RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ReNeuron Group Stock

ReNeuron Group EBIT 2024

ReNeuron Group EBIT

-6.33 M GBP

Ticker

RENE.L

ISIN

GB00BF5G6K95

WKN

A2JBKZ

In 2024, ReNeuron Group's EBIT was -6.33 M GBP, a -11.13% increase from the -7.12 M GBP EBIT recorded in the previous year.

The ReNeuron Group EBIT history

YEAREBIT (undefined GBP)
2026e-11.67
2025e4.89
2024e-6.33
2023-7.12
2022-11.23
2021-12.99
2020-14.41
2019-18.3
2018-20.38
2017-18.3
2016-13.72
2015-10.39
2014-7.97
2013-7.09
2012-6.88
2011-6.67
2010-3.91
2009-4.69
2008-6.9
2007-5.96
2006-5.94
2005-3.34
2004-1.25

ReNeuron Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ReNeuron Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ReNeuron Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ReNeuron Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ReNeuron Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ReNeuron Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ReNeuron Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ReNeuron Group’s growth potential.

ReNeuron Group Revenue, EBIT and net profit per share

DateReNeuron Group RevenueReNeuron Group EBITReNeuron Group Net Income
2026e1.19 M undefined-11.67 M undefined-11.23 M undefined
2025e12.23 M undefined4.89 M undefined103,935.06 undefined
2024e660,540 undefined-6.33 M undefined103,935.06 undefined
2023530,000 undefined-7.12 M undefined-5.41 M undefined
2022400,000 undefined-11.23 M undefined-9.69 M undefined
2021260,000 undefined-12.99 M undefined-11.35 M undefined
20206.07 M undefined-14.41 M undefined-11.41 M undefined
201950,000 undefined-18.3 M undefined-14.35 M undefined
201840,000 undefined-20.38 M undefined-17.62 M undefined
201750,000 undefined-18.3 M undefined-15.57 M undefined
201630,000 undefined-13.72 M undefined-11.35 M undefined
201530,000 undefined-10.39 M undefined-8.91 M undefined
201420,000 undefined-7.97 M undefined-7.07 M undefined
201320,000 undefined-7.09 M undefined-6.35 M undefined
201240,000 undefined-6.88 M undefined-6.23 M undefined
201130,000 undefined-6.67 M undefined-6.15 M undefined
201030,000 undefined-3.91 M undefined-5.85 M undefined
200990,000 undefined-4.69 M undefined-3.67 M undefined
200830,000 undefined-6.9 M undefined-6.57 M undefined
200750,000 undefined-5.96 M undefined-5.25 M undefined
200610,000 undefined-5.94 M undefined-6.37 M undefined
20050 undefined-3.34 M undefined-3.21 M undefined
20040 undefined-1.25 M undefined-810,000 undefined

ReNeuron Group stock margins

The ReNeuron Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ReNeuron Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ReNeuron Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ReNeuron Group's sales revenue. A higher gross margin percentage indicates that the ReNeuron Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ReNeuron Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ReNeuron Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ReNeuron Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ReNeuron Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ReNeuron Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ReNeuron Group Margin History

ReNeuron Group Gross marginReNeuron Group Profit marginReNeuron Group EBIT marginReNeuron Group Profit margin
2026e100 %-978.84 %-942.38 %
2025e100 %39.99 %0.85 %
2024e100 %-957.95 %15.73 %
2023100 %-1,343.4 %-1,020.75 %
2022100 %-2,807.5 %-2,422.5 %
2021100 %-4,996.15 %-4,365.39 %
2020100 %-237.4 %-187.97 %
2019100 %-36,600 %-28,700 %
2018100 %-50,950 %-44,050 %
2017100 %-36,600 %-31,140 %
2016100 %-45,733.33 %-37,833.33 %
2015100 %-34,633.33 %-29,700 %
2014100 %-39,850 %-35,350 %
2013100 %-35,450 %-31,750 %
2012100 %-17,200 %-15,575 %
2011100 %-22,233.33 %-20,500 %
2010100 %-13,033.33 %-19,500 %
2009100 %-5,211.11 %-4,077.78 %
2008100 %-23,000 %-21,900 %
2007100 %-11,920 %-10,500 %
2006100 %-59,400 %-63,700 %
2005100 %0 %0 %
2004100 %0 %0 %

ReNeuron Group Aktienanalyse

What does ReNeuron Group do?

The ReNeuron Group PLC is a British biopharmaceutical company specializing in the development of novel therapies for the treatment of neurological diseases such as stroke, Parkinson's, and spinal cord injuries. It was founded in 1997 and is headquartered in Guildford, Surrey. ReNeuron initially focused on researching stem cells, particularly neural stem cells, to use them for the regeneration of nerve tissue. This innovative method was intended to revolutionize the treatment of brain and spinal cord injuries. In 2006, the company successfully developed and conducted clinical trials on the first neural stem cell therapy candidate. However, the development of cellular therapies posed challenges, particularly in terms of product safety and efficacy. Therefore, ReNeuron adjusted its business strategy and has since been working on the development of exosomal products and bioproducts. Exosomes are small membrane vesicles secreted by cells. The proteins, nucleic acids, and lipids contained within them play a crucial role in cellular processes and could represent a new class of therapeutic agents. With these two new focuses, ReNeuron aims to continue being innovative and maintain its position as a leader in the biotech industry. The ReNeuron Group PLC is divided into three main areas: Core Business, NeuDiscovery, and Incubator. The Core Business is dedicated to the development and commercialization of novel therapeutic approaches for neurological diseases. The company works on the development of exosomal products, bioproducts, and cell-based therapies to aid in brain and spinal cord injuries. In developing these products, the company collaborates closely with leading research institutions, universities, and other biopharma companies. In NeuDiscovery, ReNeuron follows an "Open-Platform" strategy and provides external researchers with access to its exosomal drug library. The company expects this to lead to the discovery of new therapeutic approaches and the application of its own technology in other areas of medicine. Incubator is an internal initiative aimed at creating and supporting start-up biotech companies. The company offers its technology and expertise to this division and invests in promising projects. ReNeuron has also brought several significant products to the market in the past, including an experimental drug for the treatment of strokes based on neural stem cells. This therapeutic program has the potential to be a groundbreaking approach in stroke treatment, reducing the need for long-term medical interventions such as rehabilitation. Overall, ReNeuron is a strong force in the biotech industry and has the potential to revolutionize the face of medicine. The company has proven its ability to develop innovative and effective therapies while also adapting its business strategy to meet the regulations of the biopharmaceutical environment. ReNeuron Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing ReNeuron Group's EBIT

ReNeuron Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ReNeuron Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ReNeuron Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ReNeuron Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ReNeuron Group stock

How much did ReNeuron Group achieve in EBIT for the current year?

In the current year, ReNeuron Group has achieved an EBIT of -6.33 M GBP.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company ReNeuron Group.

How has the EBIT of ReNeuron Group developed in recent years?

The EBIT of ReNeuron Group has increased by -11.129% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company ReNeuron Group?

The EBIT of ReNeuron Group is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does ReNeuron Group pay?

Over the past 12 months, ReNeuron Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ReNeuron Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of ReNeuron Group?

The current dividend yield of ReNeuron Group is .

When does ReNeuron Group pay dividends?

ReNeuron Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ReNeuron Group?

ReNeuron Group paid dividends every year for the past 0 years.

What is the dividend of ReNeuron Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is ReNeuron Group located?

ReNeuron Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von ReNeuron Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ReNeuron Group from 10/6/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did ReNeuron Group pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of ReNeuron Group in the year 2023?

In the year 2023, ReNeuron Group distributed 0 GBP as dividends.

In which currency does ReNeuron Group pay out the dividend?

The dividends of ReNeuron Group are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ReNeuron Group

Our stock analysis for ReNeuron Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReNeuron Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.